← SS Innovations International Inc. Common Stock overview

SS Innovations International Inc. Common Stock vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

SS Innovations International Inc. Common Stock (SSII)

Q3 2026
▲3

SSII's surgical robot adoption accelerates; losses and financing remain the drag

  • Installed base and procedure volumes keep climbing SSi Mantra systems installed rose to 244 by late September, up 45% from end-2025, with 14,503 cumulative procedures and 195 telesurgeries. More machines placed and more surgeries done means more recurring revenue and proof the robot works, which supports the stock.

    This is the core demand engine behind SSII's growth story this period.

  • Record quarterly sales and a beat on installations Q2 revenue hit $13.9 million, up 39% year over year, with 30 systems installed versus the 25 analysts expected and procedures up 143%. Beating expectations on both sales and placements tells investors the business is scaling faster than thought, lifting the stock.

    It shows the financial results that validate the adoption trend.

  • New markets and training widen the runway SSII launched Sri Lanka's first robotic cardiac program, added programs in Colombia and India, and graduated 33 surgeons from seven countries in its first cardiac training class. Training doctors and opening new countries builds future demand and locks in the SSi Mantra ecosystem.

    Geographic and clinical expansion is a fresh driver of future sales.

  • Strong growth but still losing money and needing cash Zacks started coverage with a Neutral rating, noting first-half revenue of $25 million and gross profit of $12.4 million, but also a $6.2 million net loss, reliance on outside financing, and tough competition. Growth is real, but profits and funding needs cap the upside for now.

    It is the main counterweight investors must weigh against the growth story.

August 2026
▲3

SSII's surgical robot adoption accelerates; losses and financing remain the drag

  • Installed base and procedure volumes keep climbing SSi Mantra systems installed rose to 244 by late September, up 45% from end-2025, with 14,503 cumulative procedures and 195 telesurgeries. More machines placed and more surgeries done means more recurring revenue and proof the robot works, which supports the stock.

    This is the core demand engine behind SSII's growth story this period.

  • Record quarterly sales and a beat on installations Q2 revenue hit $13.9 million, up 39% year over year, with 30 systems installed versus the 25 analysts expected and procedures up 143%. Beating expectations on both sales and placements tells investors the business is scaling faster than thought, lifting the stock.

    It shows the financial results that validate the adoption trend.

  • New markets and training widen the runway SSII launched Sri Lanka's first robotic cardiac program, added programs in Colombia and India, and graduated 33 surgeons from seven countries in its first cardiac training class. Training doctors and opening new countries builds future demand and locks in the SSi Mantra ecosystem.

    Geographic and clinical expansion is a fresh driver of future sales.

  • Strong growth but still losing money and needing cash Zacks started coverage with a Neutral rating, noting first-half revenue of $25 million and gross profit of $12.4 million, but also a $6.2 million net loss, reliance on outside financing, and tough competition. Growth is real, but profits and funding needs cap the upside for now.

    It is the main counterweight investors must weigh against the growth story.

Latest
▲3

SSII's surgical robot adoption accelerates; losses and financing remain the drag

  • Installed base and procedure volumes keep climbing SSi Mantra systems installed rose to 244 by late September, up 45% from end-2025, with 14,503 cumulative procedures and 195 telesurgeries. More machines placed and more surgeries done means more recurring revenue and proof the robot works, which supports the stock.

    This is the core demand engine behind SSII's growth story this period.

  • Record quarterly sales and a beat on installations Q2 revenue hit $13.9 million, up 39% year over year, with 30 systems installed versus the 25 analysts expected and procedures up 143%. Beating expectations on both sales and placements tells investors the business is scaling faster than thought, lifting the stock.

    It shows the financial results that validate the adoption trend.

  • New markets and training widen the runway SSII launched Sri Lanka's first robotic cardiac program, added programs in Colombia and India, and graduated 33 surgeons from seven countries in its first cardiac training class. Training doctors and opening new countries builds future demand and locks in the SSi Mantra ecosystem.

    Geographic and clinical expansion is a fresh driver of future sales.

  • Strong growth but still losing money and needing cash Zacks started coverage with a Neutral rating, noting first-half revenue of $25 million and gross profit of $12.4 million, but also a $6.2 million net loss, reliance on outside financing, and tough competition. Growth is real, but profits and funding needs cap the upside for now.

    It is the main counterweight investors must weigh against the growth story.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 2026
▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

  • First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.

    This is the core new event that directly explains the profit surge and its cause.

  • Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.

    It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.

  • Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.

    It shows the market's cumulative response to the profit news, indicating sustained upward momentum.

  • Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.

    It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 2026
▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

  • First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.

    This is the core new event that directly explains the profit surge and its cause.

  • Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.

    It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.

  • Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.

    It shows the market's cumulative response to the profit news, indicating sustained upward momentum.

  • Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.

    It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest
▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

  • First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.

    This is the core new event that directly explains the profit surge and its cause.

  • Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.

    It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.

  • Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.

    It shows the market's cumulative response to the profit news, indicating sustained upward momentum.

  • Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.

    It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.